Comparison timestamp: 2025-05-08 16:52:18 UTC
RestoredCDC URL: http://restoredcdc.org/www.cdc.gov/niosh-rtecs/UB42C1D8.html
Live cdc.gov URL ↗: https://www.cdc.gov/niosh-rtecs/UB42C1D8.html
RestoredCDC URL: http://restoredcdc.org/www.cdc.gov/niosh-rtecs/UB42C1D8.html
Live cdc.gov URL ↗: https://www.cdc.gov/niosh-rtecs/UB42C1D8.html
Removed: Line removed from cdc.gov. Specific word removals are highlighted.
Added: Line added to cdc.gov. Specific word additions are highlighted.
Injected:
Line or disclaimer added by RestoredCDC.org.
Unchanged: Line unchanged.
Original site: www.cdc.gov/niosh-rtecs/UB42C1D8.html | RestoredCDC.org is an independent project, not affiliated with CDC or any federal entity. Visit CDC.gov for free official information. Due to archival on January 6, 2025, recent outbreak data is unavailable. Videos are not restored. Access data.restoredcdc.org for restored data. Use of this site implies acceptance of this disclaimer.[More]About Us Report Bug Compare ContentSkip directly to page optionsThe National Institute for Occupational Safety and Health (NIOSH)Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting PeopleSearchSearch Menu Navigation Menu× NIOSHNIOSH All CDCSubmit* Licensing Agreement Signed for RTECS* How Do I Access the RTECS Database?* Features of the RTECS Database* The National Institute for Occupational Safety and Health (NIOSH) HomeThe National Institute for Occupational Safety and Health (NIOSH)1. Registry of Toxic Effects of Chemical Substances (RTECS)1-Propanol, 2,3-epoxy-Related PagesRTECS #UB4375000CAS #556-52-5See: NMAM or OSHA MethodsUpdatedMarch 2019Molecular Weight74.09Molecular FormulaC3H6O2Synonyms2,3-Epoxy-1-propanol (ACGIH:OSHA)2,3-Epoxypropanol3-Hydroxy-1,2-epoxypropaneEpihydrin alcoholGlycideGlycidolGlycidol (ACGIH:OSHA)Glycidyl alcoholMethanol, oxiranyl-NCI-C55549Skin and Eye Irritation and ReferencesRoute/Organism Dose Effect Referenceeye /rabbit 2 mg/24H severe 85JCAE -,769,1986skin /rabbit 558 mg/3D moderate AMIHAB 14,250,1956skin /rabbit 100 mg/24H moderate 85JCAE -,769,1986Mutation Data and ReferenceSystem Test Route/Organism/Tissue Dose ReferenceCytogenetic Analysis lymphocyte/human 400 µmol/L MUREAV 91,243,1981Cytogenetic Analysis intraperitoneal/rat 320 mg/kg FCTOD7 22,665,1984Cytogenetic Analysis oral/rat 600 mg/kg FCTOD7 22,665,1984Cytogenetic Analysis ovary/hamster 12500 µg/L NTPTR* NTP-TR-374,1990Cytogenetic Analysis lung/hamster 250 mg/L/6H FCTOD7 50,3927,2012Cytogenetic Analysis lung/hamster 100 mg/L/24H FCTOD7 50,3927,2012Cytogenetic Analysis lung/hamster 60 mg/L/48H FCTOD7 50,3927,2012DNA Damage ovary/hamster 20 mg/L/3H FCTOD7 45,41,2007DNA Damage other cell types/mouse 0.31 mmol/L MUREAV 715,25,2011DNA Damage oral/rat 400 mg/kg/1D MUREAV 769,1,2014DNA Damage kidney/rat 20 mg/L/24H FCTOD7 89,1,2016DNA Damage kidney/human 20 mg/L/24H FCTOD7 89,1,2016DNA Damage ovary/hamster 10 mmol/L/1H MUREAV 805,38,2016DNA repair /Escherichia coli 10 gm/L MUREAV 130,141,1984gene conversion and mitotic recombination /Saccharomyes cerevisiae 2500 ppm JJIND8 62,901,1979heritable translocation test oral/Drosophila melanogaster 1230 ppm NTPTR* NTP-TR-374,1990micronucleus test intraperitoneal/mouse 120 mg/kg FCTOD7 100,168,2017micronucleus test oral/mouse 200 mg/kg/2D FCTOD7 50,3927,2012morphological transform embryo/hamster 10 µg/L IJCNAW 19,642,1977morphological transform fibroblast/mouse 0.001 pph/21D (-enzymatic activation step) EMMUEG 37,231,2001mutation in mammalian somatic cells lymphocyte/mouse 1250 µg/kg NTPTR* NTP-TR-374,1990mutation in mammalian somatic cells lung/hamster 1 µmol/L CRNGDP 11,497,1990mutation in microorganisms /Salmonella typhimurium 2500 µg/plate/48H FCTOD7 50,3927,2012mutation in microorganisms /Neurospora crassa 500 mmol/L (-enzymatic activation step) GENTAE 40,890,1955mutation in microorganisms /Klebsiella pneumoniae 200 µmol/L (-enzymatic activation step) MUREAV 89,269,1981mutation in microorganisms /Salmonella typhimurium 3 µg/plate (+enzymatic activation step) MUREAV 172,105,1986mutation in microorganisms /Escherichia coli 500 µmol/L (-enzymatic activation step) TOLED5 4,103,1979other mutation test systems /Escherichia coli 1 mmol/L MUREAV 231,205,1990sex chromosome loss and nondisjunction oral/Drosophila melanogaster 3690 ppm NTPTR* NTP-TR-374,1990sister chromatid exchange lymphocyte/human 50 µmol/L MUREAV 91,243,1981sister chromatid exchange ovary/hamster 10100 µg/L NTPTR* NTP-TR-374,1990sister chromatid exchange lung/hamster 1250 µmol/L MUREAV 249,55,1991specific locus test other cell types/mouse 30 gm/L/24H EMMUEG 45,80,2005Reproductive Effects Data and ReferencesRoute/Organism Dose Effect Referenceintraperitoneal/rat 500 mg/kg (5D male) Reproductive: Effects on fertility: Male fertility index (e.g., # males impregnating females per # males exposed to fertile nonpregnant females) BCSTB5 1,523,1973oral/mouse 2 gm/kg (6-15D pregnant) Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) JTEHD6 9,87,1982oral/mouse 6825 mg/kg (13W male) Reproductive: Paternal effects: Spermatogenesis (including genetic material, sperm morphology, motility, and count) NTPTR* NTP-TR-374,1990oral/rat 180 mg/kg (12D male) Reproductive: Effects on fertility: Male fertility index (e.g., # males impregnating females per # males exposed to fertile nonpregnant females) NATUAS 226,87,1970Reproductive: Paternal effects: Spermatogenesis (including genetic material, sperm morphology, motility, and count)oral/rat 18200 mg/kg (13W male) NTPTR* NTP-TR-374,1990Reproductive: Paternal effects: Testes, epididymis, sperm ductTumorigenic Data and ReferencesRoute/Organism Dose Effect ReferenceTumorigenic: Carcinogenic by RTECS criteriaoral/mouse lowest published toxic dose: 25750 mg/kg/2Y- continuous Gastrointestinal: Tumors NTPTR* NTP-TR-374,1990Skin and Appendages: TumorsTumorigenic: Carcinogenic by RTECS criteriaoral/mouse lowest published toxic dose: 12875 mg/kg/103W- intermittent Gastrointestinal: Tumors NTIS** PB90-259094Liver: TumorsTumorigenic: Carcinogenic by RTECS criteriaoral/mouse lowest published toxic dose: 12875 mg/kg/103W- intermittent Endocrine: Tumors NTIS** PB90-259094Skin and Appendages: TumorsTumorigenic: Carcinogenic by RTECS criteriaoral/rat lowest published toxic dose: 19312.5 mg/kg/103W- intermittent Brain and Coverings: Tumors NTIS** PB90-259094Skin and Appendages: TumorsTumorigenic: Carcinogenic by RTECS criteriaoral/rat lowest published toxic dose: 19312.5 mg/kg/103W- intermittent Gastrointestinal: Tumors NTIS** PB90-259094Skin and Appendages: TumorsTumorigenic: Carcinogenic by RTECS criteriaoral/rat lowest published toxic dose: 38625 mg/kg/2Y- continuous Gastrointestinal: Tumors NTPTR* NTP-TR-374,1990Skin and Appendages: TumorsAcute Toxicity Data and ReferencesRoute/Organism Dose Effect ReferenceIn Vitro/Hamster, lung Inhibitor Concentration (50 percent kill): 217 mg/L/6H In Vitro Toxicity Studies: Cell Viability (cell death), unspecified assay FCTOD7 50,3927,2012In Vitro/Hamster, lung Inhibitor Concentration (50 percent kill): 105.4 mg/L/24H In Vitro Toxicity Studies: Cell Viability (cell death), unspecified assay FCTOD7 50,3927,2012In Vitro/Hamster, lung Inhibitor Concentration (50 percent kill): 50.1 mg/L/48H In Vitro Toxicity Studies: Cell Viability (cell death), unspecified assay FCTOD7 50,3927,2012In Vitro/Human, kidney Inhibitor Concentration Low: 60 mg/L/24H In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. FCTOD7 89,1,2016In Vitro/Rat, kidney Inhibitor Concentration Low: 60 mg/L/24H In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. FCTOD7 89,1,2016inhalation/mouse lowest published toxic concentration: 100 mg/m3/4H TPKVAL 15,97,1979Lung, Thorax, or Respiration: Emphysemainhalation/mouse lethal concentration (50 percent kill): 450 ppm/4H AMIHAB 14,250,1956Lung, Thorax, or Respiration: Other changesBehavioral: Change in motor activity (specific assay)inhalation/mouse lethal concentration (50 percent kill): 1069 mg/m3/4H Lung, Thorax, or Respiration: Other changes TPKVAL 15,97,1979Nutritional and Gross Metabolic: Body temperature decreaseinhalation/rat lethal concentration (50 percent kill): 1260 mg/m3/4H TPKVAL 15,97,1979Lung, Thorax, or Respiration: Emphysemainhalation/rat lethal concentration (50 percent kill): 580 ppm/8H AMIHAB 14,250,1956Lung, Thorax, or Respiration: Other changesinhalation/rat lowest published toxic concentration: 100 mg/m3/4H TPKVAL 15,97,1979intraperitoneal/mouse lethal dose (50 percent kill): 500 mg/kg PSEBAA 35,98,1936intraperitoneal/mouse lowest published toxic dose: 30 mg/kg Blood: Other changes FCTOD7 100,168,2017intraperitoneal/rat lethal dose (50 percent kill): 200 mg/kg FCTXAV 19,347,1981Eye: Lacrimationocular/rabbit lowest published toxic dose: 100 pph TPKVAL 15,97,1979Eye: Conjunctiva irritationoral/mouse lethal dose (50 percent kill): 431 mg/kg GTPZAB 24(3),42,1980Behavioral: Change in motor activity (specific assay)oral/mouse lethal dose (50 percent kill): 431 mg/kg Lung, Thorax, or Respiration: Other changes TPKVAL 15,97,1979Nutritional and Gross Metabolic: Body temperature decreaseoral/rat lethal dose (50 percent kill): 420 mg/kg FCTXAV 19,347,1981oral/rat lowest published toxic dose: 400 mg/kg Nutritional and Gross Metabolic: Weight loss or decreased weight gain MUREAV 769,1,2014oral/rat lowest published toxic dose: 800 mg/kg Kidney, Ureter, and Bladder: Other changes MUREAV 769,1,2014skin/rabbit lethal dose (50 percent kill): 1980 mg/kg AMIHAB 14,250,1956Other Multiple Dose Data and ReferencesRoute/Organism Dose Effect Referenceinhalation/guinea pig lowest published toxic concentration: 125 mg/m3/4H/17W- intermittent Brain and Coverings: Recordings from specific areas of CNS GTPZAB 24(3),42,1980Brain and Coverings: Recordings from specific areas of CNSinhalation/rat lowest published toxic concentration: 125 mg/m3/4H/17W- intermittent Lung, Thorax, or Respiration: Respiratory stimulation GTPZAB 24(3),42,1980Nutritional and Gross Metabolic: Other changesoral/mouse lowest published toxic dose: 9600 mg/kg/16D- intermittent Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field NTPTR* NTP-TR-374,1990Brain and Coverings: Demyelinationoral/mouse lowest published toxic dose: 27300 mg/kg/13W- intermittent Kidney, Ureter, and Bladder: Changes in tubules (including acute renal failure, acute tubular necrosis) NTPTR* NTP-TR-374,1990Related to Chronic Data: Death in the "MULTIPLE DOSE" data type fieldLiver: Changes in liver weightoral/mouse lowest published toxic dose: 3500 mg/kg/14D- intermittent Kidney, Ureter, and Bladder: Changes in kidney weight NTPTR* IMM-91019Immunological Including Allergic: Decrease in cellular immune responseImmunological Including Allergic: Decreased immune responseoral/mouse lowest published toxic dose: 3500 mg/kg/14D- intermittent NTPTR* IMM-91019Immunological Including Allergic: Increased immune responseBlood: Normocytic anemiaoral/mouse lowest published toxic dose: 350 mg/kg/14D- intermittent Blood: Changes in erythrocyte (RBC) count NTPTR* IMM-91019Immunological Including Allergic: Increase in cellular immune responseBrain and Coverings: Other degenerative changesoral/rat lowest published toxic dose: 5600 mg/kg/28D- intermittent TOLED5 224,424,2014Nutritional and Gross Metabolic: Weight loss or decreased weight gainoral/rat lowest published toxic dose: 5600 mg/kg/28D- intermittent Brain and Coverings: Other degenerative changes TXAPA9 279,150,2014oral/rat lowest published toxic dose: 5600 mg/kg/28D- intermittent TXAPA9 279,150,2014oral/rat lowest published toxic dose: 9600 mg/kg/16D- intermittent Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field NTPTR* NTP-TR-374,1990Brain and Coverings: Other degenerative changesoral/rat lowest published toxic dose: 36400 mg/kg/13W- intermittent Kidney, Ureter, and Bladder: Changes in tubules (including acute renal failure, acute tubular necrosis) NTPTR* NTP-TR-374,1990Endocrine: Other changesReviewsOrganization Standard ReferenceAmerican Conference of Governmental Industrial Hygienists (ACGIH) Threshold Limit Value-time-weighted average 2 ppm DTLVS* TLV/BEI,2013American Conference of Governmental Industrial Hygienists (ACGIH) Threshold Limit Value-Confirmed animal carcinogen DTLVS* TLV/BEI,2013International Agency for Research on Cancer (IARC) Cancer Review:Animal Sufficient Evidence IMEMDT 77,564,2000International Agency for Research on Cancer (IARC) Cancer Review:Human Inadequate Evidence IMEMDT 77,564,2000International Agency for Research on Cancer (IARC) Cancer Review:Human No Adequate Data IMEMDT 77,564,2000International Agency for Research on Cancer (IARC) Cancer Review:Group 2A IMEMDT 77,564,2000TOXICOLOGY REVIEW FCTOD7 44,1699,2006TOXICOLOGY REVIEW MUREAV 584,1,2005TOXICOLOGY REVIEW MUREAV 672,17,2009TOXICOLOGY REVIEW HTOPA* 1,501,2002TOXICOLOGY REVIEW MUREAV 751,49,2012TOXICOLOGY REVIEW MUREAV 769,34,2014TOXICOLOGY REVIEW MUREAV 783,66,2015TOXICOLOGY REVIEW MUREAV 802,1,2016TOXICOLOGY REVIEW MUTAEX 31,347,2016TOXICOLOGY REVIEW RTOPDW 53,134,2009TOXICOLOGY REVIEW RTOPDW 55,52,2009TOXICOLOGY REVIEW MUTAEX 33,179,2018Standards and RegulationsOrganization Standard ReferenceMine Safety and Health Administration (MSHA) STANDARD-air time-weighted average 50 ppm (150 mg/m3) DTLVS* 3,121,1971Occupational Exposure Limit IN ARGENTINA, BULGARIA, COLOMBIA, JORDAN check ACGIH TLV;Occupational Exposure Limit IN SINGAPORE, VIETNAM check ACGIH TLVOccupational Exposure Limit-AUSTRALIA time-weighted average 25 ppm (76 mg/m3), JUL2008Occupational Exposure Limit-AUSTRIA TRK -TMW 50 ppm (150 mg/m3);KZW 50 ppm (150 mg/m3), skin, sen, 2007Occupational Exposure Limit-BELGIUM time-weighted average 2 ppm (6.2 mg/m3), MAR2002Occupational Exposure Limit-DENMARK ceiling concentration 0.2 ppm (1 mg/m3), carc, MAY2011Occupational Exposure Limit-FINLAND time-weighted average 2 ppm (6.1 mg/m3), skin, NOV2011Occupational Exposure Limit-FRANCE VME 25 ppm (75 mg/m3), C2 Carcinogen, FEB2006Occupational Exposure Limit-ICELAND short term exposure limit 0.2 ppm (1 mg/m3), NOV2011Occupational Exposure Limit-JAPAN 2A carc, MAY2012Occupational Exposure Limit-KOREA time-weighted average 25 ppm (75 mg/m3), 2006Occupational Exposure Limit-MEXICO time-weighted average 25 ppm (75 mg/m3);short term exposure limit 100 ppm (300 mg/m3), 2004Occupational Exposure Limit-NEW ZEALAND time-weighted average 25 ppm (76 mg/m3), JAN2002Occupational Exposure Limit-NORWAY time-weighted average 25 ppm (75 mg/m3), JAN1999Occupational Exposure Limit-PERU time-weighted average 2 ppm (6 mg/m3), JUL2005Occupational Exposure Limit-RUSSIA short term exposure limit 5 mg/m3, JUN2003Occupational Exposure Limit-SWITZERLAND carc 2, JAN2011Occupational Exposure Limit-THE PHILIPPINES time-weighted average 50 ppm (150 mg/m3), JAN1993Occupational Exposure Limit-TURKEY time-weighted average 50 ppm (150 mg/m3), JAN1993Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (Construction) 8H time-weighted average 50 ppm (150 mg/m3) CFRGBR 29,1926.55,1994Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (Federal Contractors) 8H time-weighted average 50 ppm (150 mg/m3) CFRGBR 41,50-204.50,1994Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (General Industry) 8H time-weighted average 50 ppm (150 mg/m3) CFRGBR 29,1910.1000,1994Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (Shipyards) 8H time-weighted average 50 ppm (150 mg/m3) CFRGBR 29,1915.1000,1993NIOSH Documentation and SurveillanceOrganization Standard ReferenceNational Institute for Occupational Safety and Health (NIOSH) Recommended Exposure Level TO GLYCIDOL-air 10H time-weighted average 25 ppm NIOSH* DHHS #92-100,1992National Occupational Exposure Survey 1983 Hazard Code 35120; Number of Industries 3; Total Number of Facilities 88; Number of Occupations 10; Total Number of Employees Exposed 4872; Total Number of Female Employees Exposed 580Status in Federal AgenciesOrganization ReferenceEPA GENETOX PROGRAM 1988, Inconclusive: SHE-clonal assayEPA GENETOX PROGRAM 1988, Negative: In vitro UDS-human fibroblastEPA GENETOX PROGRAM 1988, Positive: Histidine reversion-Ames test; S cerevisiae-homozygosisEPA GENETOX PROGRAM 1988, Positive: N crassa-reversion; E coli polA without S9EPA GENETOX PROGRAM 1988, Positive: S pombe-reversionEPA TSCA 8(a) PRELIMINARY ASSESSMENT INFORMATION, FINAL RULE FEREAC 47,26992,82EPA TSCA Section 8(b) CHEMICAL INVENTORYEPA TSCA Section 8(d) unpublished health/safety studiesEPA TSCA TEST SUBMISSION (TSCATS) DATA BASE, JANUARY 2001NCI Carcinogenesis Studies (gavage);clear evidence:mouse,ratNIOSH Analytical Method, 1994: Glycidol, 1608NTP 14th Report on Carcinogens,2016:Reasonably anticipated to be human carcinogenNTP Carcinogenesis studies; on test (prechronic studies), October 2000Page last reviewed: November 16, 2018Content source: National Institute for Occupational Safety and Health* SyndicateRegistry of Toxic Effects of Chemical Substances (RTECS)* Licensing Agreement Signed for RTECS* How Do I Access the RTECS Database?* Features of the RTECS DatabaseFollow NIOSH* YouTubeNIOSH Homepage* Workplace Safety & Health Topics* Publications and Products* Programs* Contact NIOSH* About CDC* Contact Us* 800-232-4636Facebook Twitter Instagram LinkedIn Youtube Pinterest SnapchatFacebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat RSS* CONTACT CDCContact UsCall 800-232-4636Email Us* ABOUT CDC+ About CDC+ Jobs+ Funding* POLICIES+ Accessibility+ External Links+ Privacy+ Policies+ Web Policies+ No Fear Act+ FOIA+ OIG+ No Fear Act+ Nondiscrimination+ Vulnerability Disclosure Policy+ CDC Archive+ Public Health Publications+ HHS.gov+ USA.gov* CONNECT WITH US+ Youtube+ Snapchat* LANGUAGES+ Español+ 繁體中文+ Tiếng Việt+ 한국어+ Tagalog+ Русский+ العربية+ Kreyòl Ayisyen+ Français+ Polski+ Português+ Italiano+ Deutsch+ 日本語+ فارسی+ English* U.S. Department of Health & Human Services* Accessibility* External Links* Privacy* Policies* Web Policies* FOIA* OIG* No Fear Act* FOIA* Nondiscrimination* OIG* Vulnerability Disclosure Policy* CDC Archive* Public Health Publications* HHS.gov* USA.govContent Credential×This image was edited or created using GenAI (generative artificial intelligence).Our experts review all images in an effort to ensure accuracy and quality before use.Learn more about CDC's usage of GenAI.Exit Notification/Disclaimer PolicyCloseLinks with this icon indicate that you are leaving the CDC website.* The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.* Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.* You will be subject to the destination website's privacy policy when you follow the link.* CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.For more information on CDC's web notification policies, see Website Disclaimers.Cancel Continue
Note: Comparison ignores leading/trailing whitespace
and certain script/tracking codes. Word-level
highlighting (optional above) only applies to changed
lines.